nirsevimab-alip (Beyfortus)
nirsevimab-alip is an FDA-licensed reference biologic from Sanofi Vaccines US Inc..
Reference product
Beyfortus nirsevimab-alip
Sanofi Vaccines US Inc.
View full reference-product record- Approved
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Molecular structure
Experimental 3D structure for nirsevimab-alip from the RCSB Protein Data Bank (PDB 5UDC).
Interactive biological assembly from PDB entry 5UDC. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.
Exclusivity & patent cliffs
Reference approval
Approval date of the reference nirsevimab-alip product.
3 yr 3 mo ago
nirsevimab-alip: frequently asked questions
Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.
Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for nirsevimab-alip.
Related FDA reference tools
- FDA Orange BookApproved drugs, generics, therapeutic-equivalence codes, patents, and exclusivity.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
